191 related articles for article (PubMed ID: 33351121)
41. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
42. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
43. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
Canaani J; Savani BN; Labopin M; Michallet M; Craddock C; Socié G; Volin L; Maertens JA; Crawley C; Blaise D; Ljungman PT; Cornelissen J; Russell N; Baron F; Gorin N; Esteve J; Ciceri F; Schmid C; Giebel S; Mohty M; Nagler A
Am J Hematol; 2017 Aug; 92(8):789-796. PubMed ID: 28439910
[TBL] [Abstract][Full Text] [Related]
44. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
45. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
46. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
47. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
48. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
[TBL] [Abstract][Full Text] [Related]
49. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
[TBL] [Abstract][Full Text] [Related]
50. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
51. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Gorin NC; Labopin M; Blaise D; de Groot M; Socié G; Bourhis JH; Ciceri F; Polge E; Nagler A; Mohty M
Cancer; 2020 Mar; 126(5):1004-1015. PubMed ID: 31774557
[TBL] [Abstract][Full Text] [Related]
52. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).
Champlin RE; Schmitz N; Horowitz MM; Chapuis B; Chopra R; Cornelissen JJ; Gale RP; Goldman JM; Loberiza FR; Hertenstein B; Klein JP; Montserrat E; Zhang MJ; Ringdén O; Tomany SC; Rowlings PA; Van Hoef ME; Gratwohl A
Blood; 2000 Jun; 95(12):3702-9. PubMed ID: 10845900
[TBL] [Abstract][Full Text] [Related]
53. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism.
Beelen DW; Ottinger HD; Elmaagacli A; Scheulen B; Basu O; Kremens B; Havers W; Grosse-Wilde H; Schaefer UW
Blood; 1997 Dec; 90(12):4725-35. PubMed ID: 9389688
[TBL] [Abstract][Full Text] [Related]
54. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
[TBL] [Abstract][Full Text] [Related]
55. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
[TBL] [Abstract][Full Text] [Related]
56. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.
Reshef R; Huffman AP; Gao A; Luskin MR; Frey NV; Gill SI; Hexner EO; Kambayashi T; Loren AW; Luger SM; Mangan JK; Nasta SD; Richman LP; Sell M; Stadtmauer EA; Vonderheide RH; Mick R; Porter DL
J Clin Oncol; 2015 Jul; 33(21):2392-8. PubMed ID: 26056179
[TBL] [Abstract][Full Text] [Related]
57. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
58. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
[TBL] [Abstract][Full Text] [Related]
59. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.
Shouval R; Fein JA; Labopin M; Cho C; Bazarbachi A; Baron F; Bug G; Ciceri F; Corbacioglu S; Galimard JE; Giebel S; Gilleece MH; Giralt S; Jakubowski A; Montoto S; O'Reilly RJ; Papadopoulos EB; Peric Z; Ruggeri A; Sanz J; Sauter CS; Savani BN; Schmid C; Spyridonidis A; Tamari R; Versluis J; Yakoub-Agha I; Perales MA; Mohty M; Nagler A
Lancet Haematol; 2021 Mar; 8(3):e205-e215. PubMed ID: 33636142
[TBL] [Abstract][Full Text] [Related]
60. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
Corradini P; Zallio F; Mariotti J; Farina L; Bregni M; Valagussa P; Ciceri F; Bacigalupo A; Dodero A; Lucesole M; Patriarca F; Rambaldi A; Scimè R; Locasciulli A; Bandini G; Gianni AM; Tarella C; Olivieri A
J Clin Oncol; 2005 Sep; 23(27):6690-8. PubMed ID: 16170177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
